ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2022
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.Journal of global health · 2023Pooled it
- Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2022Pooled it
- Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia.Global epidemiology · 2026Article
- In vivo colonic epithelial cell editing attenuates intestinal inflammation in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Article
- Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions.Human vaccines & immunotherapeutics · 2025Article
- Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation.Nature materials · 2025Article
- Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination.BMJ neurology open · 2025Article
- Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting.Internal and emergency medicine · 2024Article
- Article
- Effectiveness and safety of immune response to SARS‑CoV‑2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta‑analysis.Biomedical reports · 2024Article
- Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVacVaccines · 2024Article
- Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants.Journal of immunology research · 2024Review
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus · 2024Review
- Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam.Human vaccines & immunotherapeutics · 2023Article
- Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients.Renal failure · 2023Article
- Risk and characteristics of Bell's palsy in adults as an adverse event following COVID-19 vaccination: a retrospective study.Acta neurologica Belgica · 2023Article
- A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors.Journal of Korean medical science · 2023Article
- Article
- Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan.Journal of epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe BNT162b2 and mRNA-1273 COVID-19 vaccines are the main vaccines that have been used for mass vaccination in Japan. Information on adverse reactions to COVID-19 vaccines in the Japanese population is limited.
methodsWe conducted an online survey on self-reported adverse reactions in individuals who had received two doses of the BNT162b2 or mRNA-1273 vaccine. The incidence of adverse events after each dose of vaccine was investigated. Propensity score matching was used to compare the incidence of adverse reactions after the second dose of the BNT162b2 and mRNA-1273 vaccines.
resultsAfter the first and second doses of the BNT162b2 vaccine, and the first and second doses of the mRNA-1273 vaccine, 890, 853, 6401, and 3965 individuals, respectively, provided complete responses. Systemic reactions, including fever, fatigue, headache, muscle/joint pain, and nausea were significantly more common in females, individuals aged <50 years, and after the second dose. The incidence of injection site pain did not differ significantly according to the dose. The incidence of delayed injection site reactions after the first dose of mRNA-1273 vaccine was 3.9% and 0.8% among females and males, respectively, and 10.6% among females aged 40-69 years. Local and systemic reactions after the second dose, including fever, fatigue, headache, muscle/joint pain, nausea, and skin rash were more common in individuals who had received the mRNA-1273 vaccine.
conclusionsAdverse reactions were more frequently reported in females, younger individuals, and after the mRNA-1273 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.